Industry: Pharmaceutical Chemistry Region: France Transaction Price: US$ 1 million Transaction Method: Equity investment
Project introduction:
A pharmaceutical chemistry laboratory in Montpellier, France, is a contract research organization (CRO) focusing on pharmaceutical chemistry, and has more than 15 years of professional experience in the synthesis of highly functional organic compounds. The team focuses on the core technology platforms, including: nucleoside (acid), phosphoramidite, polypeptide, oligosaccharide, heterocyclic compound, linker, PROTACs and route exploration.
The laboratory provides integrated pharmaceutical chemistry services and cooperates with partners in computer-aided drug design (CADD/AI) and cell/enzyme screening. The laboratory has provided drug research and development project support for international companies and research institutions, including five of the top ten pharmaceutical groups in the world, as well as biotechnology companies from Europe, Israel, North America and Japan.
The laboratory is located in a biological park in Montpellier, France, with an area of 600 square meters and equipped with advanced chemical and analytical instruments. At present, the company has 15 employees (60% have doctoral degrees and 40% have master's degrees). In 2025, the company's annual revenue reached 1.895 million euros.
Service scope:
The laboratory provides two modes of cooperation: Fee for Service (FFS) and Full-time Equivalent (FTE). The service scope includes:
Custom synthesis (from mg to 100g)
Pharmaceutical chemistry projects: discovery of emerging compounds, optimization of emerging to leading compounds, optimization of leading compounds, and nomination of preclinical candidate drugs.
Cooperation mode:
The laboratory aims to expand its customer network in Asia and may seek additional chemical resources in China. The company is willing to cooperate with investors and enterprises that can provide complementary knowledge and market channels.